Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments

Table 1 Patient and tumor characteristics at baseline (n = 32)

Characteristics	Patients, n (%)
Age (yr), median (range)	56 (19-70)
Gender
Male	21 (65.6)
Female	11 (34.4)
ECOG performance status
0	16 (50)
1	11 (34.4)
2	5 (15.6)
Underlying liver disease
HBV	23 (71.9)
Alcohol	2 (6.3)
Other	7 (21.8)
Prior therapy
Surgery	4 (12.5)
Ablation	5 (15.6)
TACE	19 (59.4)
TACE + radiotherapy	4 (12.5)
Child Pugh score
A	22 (68.8)
B	10 (31.2)
Cirrhosis
No	20 (62.5)
Yes	12 (37.5)
HBV-DNA
< 1.0e3 cps/mL	16 (69.6)
≥ 1.0e3 cps/mL	7 (30.4)
Portal vein thrombosis
No	25 (78.1)
Yes	7 (21.9)
Median AFP (ng/mL)
≥ 400	22 (68.8)
< 400	10 (31.2)
Metastasis
Lung	9 (28.1)
Bone	6 (18.8)
Adrenal gland	9 (28.1)
Lymph node	3 (9.4)
Peritoneum	3 (9.4)
Other	2 (6.2)

ECOG: Eastern Cooperation Oncology Group; HBV: Hepatitis B virus; TACE: Transarterial chemoembolization; AFP: Alpha fetoprotein.

Table 2 Treatment-related toxicities in 32 patients

Adverse event	Grade 1	Grade 2	Grade 3	Grade 4
Neutropenia	2	2	1	1
Thrombocytopenia	4	3	1	1
Anemia	5	1	0	0
Nausea/vomiting	6	3	1	0
Mucositis	4	2	0	0
Stomatitis	3	2	1	0
Diarrhoea	0	1	1	0
Transaminases	7	3	1	0
Hyperbilirubinemia	2	0	0	0
Neurotoxicity	5	8	2	0
Hand-foot syndrome	4	2	1	0

Hepatitis B virus DNA level (real-time polymerase chain reaction, Abbott, Wiesbaden, Germany).